DEBT CONVERSION AGREEMENTDebt Conversion Agreement • April 26th, 2022 • Hemoglobin Oxygen Therapeutics LLC • Delaware
THIS DEBT CONVERSION AGREEMENT (this “Agreement”) is made and entered into as of January 3, 2022, by and between Hemoglobin Oxygen Therapeutics, LLC., a Delaware limited liability company (the “Company”), and the undersigned creditor of the Company (“Purchaser”).
HEMOGLOBIN OXYGEN THERAPEUTICS, INC.Employment Agreement • April 26th, 2022 • Hemoglobin Oxygen Therapeutics LLC • Delaware
We are pleased to offer you continued employment as the full-time position of Chief Executive Officer (“CEO”) of Hemoglobin Oxygen Therapeutics, LLC (the “Company”) as of January 10, 2022. As you know, the Company plans to convert to a C corporation (“Newco”), and upon such conversion, the reference to “Company” herein shall be to Newco. This offer is contingent upon your agreement to execute the Company’s Nondisclosure, Noncompetition and Assignment of Developments Agreement (the “Nondisclosure Agreement”), a copy of which is attached hereto as Exhibit A. This letter agreement (the “Agreement”) summarizes the initial terms of your continued employment.
HEMOGLOBIN OXYGEN THERAPEUTICS, INC.Agreement of Employment • April 26th, 2022 • Hemoglobin Oxygen Therapeutics LLC • Delaware
We are pleased to offer you continued employment as the full-time position of Chief Medical Officer (“CMO”) of Hemoglobin Oxygen Therapeutics, LLC (the “Company”) as of August 1, 2022. As you know, the Company plans to convert to a C corporation (“Newco”), and upon such conversion, the reference to “Company” herein shall be to Newco. This offer is contingent upon the Company successfully closing its initial public offering, and your agreement to execute the Company’s Nondisclosure, Noncompetition and Assignment of Developments Agreement (the “Nondisclosure Agreement”), a copy of which is attached hereto as Exhibit A. This letter agreement (the “Agreement”) summarizes the initial terms of your continued employment.
